Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
NEW YORK, Dec. 09, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc. (“Osiris Therapeutics”) (NASDAQ:OSIR) between May 12, 2014 through November 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. If you purchased or otherwise acquired Osiris Therapeutics between May 12, 2014 and November 20, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/osiris-therapeutics-osir
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
